Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced notable results from Phase 2 and Phase 3 studies of setmelanotide, presented at ENDO 2021. Heterozygous (HET) obesity patients achieved a mean weight loss of 12.3% at nine months. Phase 3 data showed significant weight and hunger reduction in patients with Bardet-Biedl and Alström syndromes. Overall, the safety profile was consistent with prior findings, including common adverse events like skin hyperpigmentation and nausea. These results reinforce setmelanotide's potential in treating rare genetic obesity disorders.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced three late-breaking abstracts accepted for presentation at the ENDO 2021 Annual Meeting, occurring virtually from March 20-23. Dr. Sadaf Farooqi will present clinical data from a Phase 2 study of setmelanotide for heterozygous obesity linked to POMC, PCSK1, or LEPR gene variants. Additional presentations will cover data from a Phase 3 trial in patients with Bardet-Biedl Syndrome and safety analyses from two Phase 3 trials. Rhythm continues to advance therapies for rare genetic obesity disorders.
Rhythm Pharmaceuticals (RYTM) has received FDA approval for IMCIVREE, the first treatment for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiencies. The company reported positive topline data from a Phase 3 trial for Bardet-Biedl syndrome and is advancing a broad development program for setmelanotide, with multiple clinical studies slated for 2021. Financially, Rhythm has strengthened its position with $98.5M from a Rare Pediatric Disease PRV sale and $161.6M from a public offering, extending its cash runway through at least mid-2023.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced participation of David Meeker, M.D., CEO, in the Cowen & Co. 41st Annual Health Care Conference on March 3, 2021. He will partake in a fireside chat at 2:40 p.m. ET and a panel discussion on "New Drug Launches" at 10:20 a.m. ET. A live audio webcast will be accessible on the company's Investor Relations website, with a replay available for 30 days. Rhythm focuses on therapies for rare genetic diseases of obesity and has FDA-approved IMCIVREE™ for chronic weight management in specific genetic conditions.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced the closing of its public offering of 5,750,000 common shares at $30.00 each on February 9, 2021, raising approximately $172.5 million in gross proceeds. This included the full exercise of a 750,000-share underwriter option. The offering was facilitated by Morgan Stanley, BofA Securities, Cowen, and Stifel as joint managers and was conducted under a previously filed shelf registration. Rhythm focuses on therapies for rare genetic obesity diseases and has FDA-approved treatment IMCIVREE for specific genetic deficiencies.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a public offering of 5,000,000 shares at $30.00 each, aiming to fund its efforts in treating rare genetic obesity diseases. Additionally, underwriters have a 30-day option for 750,000 more shares. The offering, structured under an SEC shelf registration filed in 2018, is set to conclude on February 9, 2021. Morgan Stanley, BofA Securities, Cowen, and Stifel are managing the offering. The company emphasizes that this announcement is not a sales offer and acknowledges potential risks, including market conditions and clinical trial outcomes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a proposed public offering of $150 million of its common stock, with a potential additional $22.5 million if underwriters exercise their option. The offering is managed by Morgan Stanley, BofA Securities, Cowen, and Stifel, and is subject to market conditions. The shares will be offered under a shelf registration statement filed with the SEC. This move aims to bolster the company's capabilities to develop therapies for rare genetic obesity diseases.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced positive results from its Phase 2 Basket Study, demonstrating proof-of-concept for setmelanotide in patients with genetic obesity disorders. The study found that 34.3% of patients with HET obesity achieved significant weight loss. Updated data suggests that 100,000-200,000 patients in the U.S. could benefit from this treatment. Additionally, the pivotal Phase 3 trial for Bardet-Biedl Syndrome showed significant improvements in pediatric patients’ BMI-Z scores. Rhythm plans to initiate further studies to expand setmelanotide's application.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a virtual event on January 26, 2021, to present updates on its exploratory Phase 2 Basket Study and genetic sequencing efforts. Management will discuss data for setmelanotide in individuals with heterozygous obesity linked to genetic variants in POMC, PCSK1, or LEPR genes, as well as SRC1 and SH2B1 deficiency. The company has sequenced samples from approximately 37,500 individuals with severe obesity to enhance understanding and diagnosis of these conditions.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M. This voucher was granted by the FDA following the approval of IMCIVREE™ (setmelanotide) for chronic weight management in patients with genetic deficiencies causing severe obesity. The sale will provide non-dilutive capital to further develop setmelanotide, which has been approved for patients aged 6 and older. The upfront payment is conditioned on customary closing requirements, with an expected transaction completion following U.S. antitrust clearance.